Search for "guanidine" in Full Text gives 78 result(s) in Beilstein Journal of Organic Chemistry.
Beilstein J. Org. Chem. 2015, 11, 385–391, doi:10.3762/bjoc.11.44
Graphical Abstract
Scheme 1: Interaction of 2-ethoxymethylidene-3-oxo esters 1a–c with 5-AT. R = CF3 (a), (CF2)2H (b), Me (c). C...
Scheme 2: Synthesis of pyrimidines 4a,b and 5. R= CF3 (a), (CF2)2H (b). Conditions: i: 1,4-dioxane, NaOAc, Δ,...
Figure 1: X-ray crystal structure of compound 5 (ORTEP drawing, 50% probability level).
Scheme 3: Interaction of 2-ethoxymethylidene malonate 1e with 5-AT. Conditions: i: EtOH, Et3N, Δ; ii: EtOH, Δ....
Scheme 4: The reaction of 3-oxo ester 1d with 5-AT. Conditions, i: TFE, Δ, 48 h.
Scheme 5: Interaction of ester 1f with 5-AT. Conditions i: EtOH (or TFE), Et3N, Δ, 40–60 min; ii: AcOH (or Et...
Figure 2: X-ray crystal structure of compound 11 (ORTEP drawing, 50% probability level).
Beilstein J. Org. Chem. 2014, 10, 2930–2954, doi:10.3762/bjoc.10.312
Graphical Abstract
Scheme 1: The Grignard-based synthesis of 6-alkyl phenanthridine.
Scheme 2: Radical-mediated synthesis of 6-arylphenanthridine [14].
Scheme 3: A t-BuO• radical-assisted homolytic aromatic substitution mechanism proposed for the conversion of ...
Scheme 4: Synthesis of 5,6-unsubstituted phenanthridine starting from 2-iodobenzyl chloride and aniline [17].
Scheme 5: Phenanthridine synthesis initiated by UV-light irradiation photolysis of acetophenone O-ethoxycarbo...
Scheme 6: PhI(OAc)2-mediated oxidative cyclization of 2-isocyanobiphenyls with CF3SiMe3 [19,20].
Scheme 7: Targeting 6-perfluoroalkylphenanthridines [21,22].
Scheme 8: Easily accessible biphenyl isocyanides reacting under mild conditions (room temp., visible light ir...
Scheme 9: Microwave irradiation of Diels–Alder adduct followed by UV irradiation of dihydrophenanthridines yi...
Scheme 10: A representative palladium catalytic cycle.
Scheme 11: The common Pd-catalyst for the biphenyl conjugation results simultaneously in picolinamide-directed...
Scheme 12: Pd(0)-mediated cyclisation of imidoyl-selenides forming 6-arylphenanthridine derivatives [16]. The inse...
Scheme 13: Palladium-catalysed phenanthridine synthesis.
Scheme 14: Aerobic domino Suzuki coupling combined with Michael addition reaction in the presence of a Pd(OAc)2...
Scheme 15: Rhodium-catalysed alkyne [2 + 2 + 2] cycloaddition reactions [36].
Scheme 16: The O-acetyloximes derived from 2′-arylacetophenones underwent N–O bond cleavage and intramolecular ...
Scheme 17: C–H arylation with aryl chloride in the presence of a simple diol complex with KOt-Bu (top) [39]; for s...
Scheme 18: The subsequent aza-Claisen rearrangement, ring-closing enyne metathesis and Diels–Alder reaction – ...
Scheme 19: Phenanthridine central-ring cyclisation with simultaneous radical-driven phosphorylation [42].
Scheme 20: Three component reaction yielding the benzo[a]phenanthridine core in excellent yields [44].
Scheme 21: a) Reaction of malononitrile and 1,3-indandione with BEP to form the cyclised DPP products; b) pH c...
Figure 1: Schematic presentation of the intercalative binding mode by the neighbour exclusion principle and i...
Figure 2: Urea and guanidine derivatives of EB with modified DNA interactions [57].
Figure 3: Structure of mono- (3) and bis-biguanide (4) derivative. Fluorescence (y-axis normalised to startin...
Scheme 22: Bis-phenanthridinium derivatives (5–7; inert aliphatic linkers, R = –(CH2)4– or –(CH2)6–): rigidity...
Figure 4: Series of amino acid–phenanthridine building blocks (general structure 10; R = H; Gly) and peptide-...
Figure 5: General structure of 45 bis-ethidium bromide analogues. Reproduced with permission from [69]. Copyright...
Scheme 23: Top: Recognition of poly(U) by 12 and ds-polyAH+ by 13; bottom: Recognition of poly(dA)–poly(dT) by ...
Figure 6: The bis-phenanthridinium–adenine derivative 15 (LEFT) showed selectivity towards complementary UMP;...
Figure 7: The neomycin–methidium conjugate targeting DNA:RNA hybrid structures [80].
Figure 8: Two-colour RNA intercalating probe for cell imaging applications: Left: Chemical structure of EB-fl...
Figure 9: The ethidium bromide nucleosides 17 (top) and 18 (bottom). DNA duplex set 1 and 2 (E = phenanthridi...
Figure 10: Left: various DNA duplexes; DNA1 and DNA2 used to study the impact on the adjacent basepair type on...
Figure 11: Structure of 4,9-DAP derivative 19; Rright: MIAPaCa-2 cells stained with 10 μM 19 after 60 and 120 ...
Figure 12: Examples of naturally occurring phenanthridine analogues.
Beilstein J. Org. Chem. 2014, 10, 2255–2262, doi:10.3762/bjoc.10.234
Graphical Abstract
Scheme 1: Conditions: a) benzaldehyde, ethanol/water, reflux, 1 h, 96% yield; b) H2, Pd/C (10%), MeOH, rt, 48...
Scheme 2: Carbamoylation of 1,2,3-tris(benzylamino)guanidinium salts 3 and 5-OTs.
Figure 1: Solid-state structure of 7a·3CH3CN. Left: Molecular structure with numbering of atoms. Right: N–H··...
Scheme 3: Deprotonation of 7a to yield the neutral guanidine derivative 8.
Figure 2: Solid-state structure of 8. Thermal displacement ellipsoids are drawn at the 20% probability level....
Scheme 4: Sulfonylcarbamoylation of salt 3.
Figure 3: Hydrogen-bonded one-dimensional network of guanidine 8 in the solid state. The intramolecular N9···...
Scheme 5: Reaction of 1,2,3-trisbenzylaminoguanidinium chloride (3) with aryl isothiocyanates.
Figure 4: Solid-state structure of 10b. Thermal displacement ellipsoids are drawn at the 30% probability leve...
Scheme 6: Proposed mechanism of the formation of 10 and 11.
Beilstein J. Org. Chem. 2014, 10, 1959–1966, doi:10.3762/bjoc.10.204
Graphical Abstract
Scheme 1: Reactions of CO2 with amino-group containing absorbents (a), base/proton donor binary system (b) or...
Figure 1: Typical optimized structures of complex cations derived from chelation between Li+ and neutral liga...
Figure 2: (a) Comparison of the thermal stability between the neutral ligands and the corresponding chelated ...
Figure 3: In situ FTIR spectra of neutral ligands and the corresponding chelated ionic liquids after reaction...
Figure 4: Influence of the ratio of LiNTf2/neutral ligands (PEG150MeTMG and PEG150MeBu2N) on the CO2 capacity...
Figure 5: The quantum chemistry calculations (enthalpy changes) of the reaction between CO2 and [PEG150MeTMGL...
Beilstein J. Org. Chem. 2014, 10, 1914–1918, doi:10.3762/bjoc.10.199
Graphical Abstract
Scheme 1: The hypermodified nucleoside queuosine (Q) and the synthetic targets of preQ1 bases 1 to 3 with com...
Scheme 2: Synthesis of [15N1,15N3,H215N(C2)]-preQ1 base (1). a) CH3ONa (10 equiv) CH3OH, reflux, 10 h, RP C18...
Scheme 3: Synthesis of [15N9]-preQ1 base (2). a) [15N]-KCN (1 equiv), Na2CO3, H2O, pH 9, 80 °C, 3 h, then roo...
Scheme 4: Synthesis of [H215N(C7')] preQ1 base (3). a) K2CO3 (1.5 equiv), DMF, 70 °C, 14 h, 47%. b) Dess–Mart...
Figure 1: Comparison of 1H NMR spectra of the preQ1 bases 1, 2 and 3 with complementary 15N labeling patterns...
Beilstein J. Org. Chem. 2014, 10, 707–713, doi:10.3762/bjoc.10.64
Graphical Abstract
Figure 1: FTIR spectra of a) ND50-PG, b) ND-PG-OTs, c) ND-PG-N3, d) ND-PG-Arg8, e) ND-PG-Lys8, and f) ND-PG-H...
Figure 2: 1H NMR spectra of a) ND50-PG, b) ND-PG-OTs and c) ND-PG-N3 in D2O.
Figure 3: TGA profiles of ND50-PG under nitrogen and air.
Figure 4: STEM images of a) pristine ND50 and b) ND50-PG.
Scheme 1: Synthetic route from ND50 to ND-PG-BPP; i) glycidol, 140 °C, 20 h; ii) p-TsCl, pyridine, 0 °C to rt...
Figure 5: Picture of the dispersions of a) ND50-PG (20 mg/mL), b) ND-PG-Arg8, c) ND-PG-Lys8 and d) ND-PG-His8...
Figure 6: Electrophoretic migration of pDNA, NP (ND50-PG or ND-PG-BPP), and NP/pDNA mixtures at various weigh...
Beilstein J. Org. Chem. 2014, 10, 544–598, doi:10.3762/bjoc.10.50
Graphical Abstract
Scheme 1: The proposed mechanism of the Passerini reaction.
Scheme 2: The PADAM-strategy to α-hydroxy-β-amino amide derivatives 7. An additional oxidation provides α-ket...
Scheme 3: The general accepted Ugi-mechanism.
Scheme 4: Three commonly applied Ugi/cyclization approaches. a) UDC-process, b) UAC-sequence, c) UDAC-combina...
Scheme 5: Ugi reaction that involves the condensation of Armstrong’s convertible isocyanide.
Scheme 6: Mechanism of the U-4C-3CR towards bicyclic β-lactams.
Scheme 7: The Ugi 4C-3CR towards oxabicyclo β-lactams.
Scheme 8: Ugi MCR between an enantiopure monoterpene based β-amino acid, aldehyde and isocyanide resulting in...
Scheme 9: General MCR for β-lactams in water.
Scheme 10: a) Ugi reaction for β-lactam-linked peptidomimetics. b) Varying the β-amino acid resulted in β-lact...
Scheme 11: Ugi-4CR followed by a Pd-catalyzed Sn2 cyclization.
Scheme 12: Ugi-3CR of dipeptide mimics from 2-substituted pyrrolines.
Scheme 13: Joullié–Ugi reaction towards 2,5-disubstituted pyrrolidines.
Scheme 14: Further elaboration of the Ugi-scaffold towards bicyclic systems.
Scheme 15: Dihydroxyproline derivatives from an Ugi reaction.
Scheme 16: Diastereoselective Ugi reaction described by Banfi and co-workers.
Scheme 17: Similar Ugi reaction as in Scheme 16 but with different acids and two chiral isocyanides.
Scheme 18: Highly diastereoselective synthesis of pyrrolidine-dipeptoids via a MAO-N/MCR-procedure.
Scheme 19: MAO-N/MCR-approach towards the hepatitis C drug telaprevir.
Scheme 20: Enantioselective MAO-U-3CR procedure starting from chiral pyrroline 64.
Scheme 21: Synthesis of γ-lactams via an UDC-sequence.
Scheme 22: Utilizing bifunctional groups to provide bicyclic γ-lactam-ketopiperazines.
Scheme 23: The Ugi reaction provided both γ- as δ-lactams depending on which inputs were used.
Scheme 24: The sequential Ugi/RCM with olefinic substrates provided bicyclic lactams.
Scheme 25: a) The structural and dipole similarities of the triazole unit with the amide bond. b) The copper-c...
Scheme 26: The Ugi/Click sequence provided triazole based peptidomimetics.
Scheme 27: The Ugi/Click reaction as described by Nanajdenko.
Scheme 28: The Ugi/Click-approach by Pramitha and Bahulayan.
Scheme 29: The Ugi/Click-combination by Niu et al.
Scheme 30: Triazole linked peptidomimetics obtained from two separate MCRs and a sequential Click reaction.
Scheme 31: Copper-free synthesis of triazoles via two MCRs in one-pot.
Scheme 32: The sequential Ugi/Paal–Knorr reaction to afford pyrazoles.
Scheme 33: An intramolecular Paal–Knorr condensation provided under basic conditions pyrazolones.
Scheme 34: Similar cyclization performed under acidic conditions provided pyrazolones without the trifluoroace...
Scheme 35: The Ugi-4CR towards 2,4-disubstituted thiazoles.
Scheme 36: Solid phase approach towards thiazoles.
Scheme 37: Reaction mechanism of formation of thiazole peptidomimetics containing an additional β-lactam moiet...
Scheme 38: The synthesis of the trisubstituted thiazoles could be either performed via an Ugi reaction with pr...
Scheme 39: Performing the Ugi reaction with DMB-protected isocyanide gave access to either oxazoles or thiazol...
Scheme 40: Ugi/cyclization-approach towards 2,5-disubstituted thiazoles. The Ugi reaction was performed with d...
Scheme 41: Further derivatization of the thiazole scaffold.
Scheme 42: Three-step procedure towards the natural product bacillamide C.
Scheme 43: Ugi-4CR to oxazoles reported by Zhu and co-workers.
Scheme 44: Ugi-based synthesis of oxazole-containing peptidomimetics.
Scheme 45: TMNS3 based Ugi reaction for peptidomimics containing a tetrazole.
Scheme 46: Catalytic cycle of the enantioselective Passerini reaction towards tetrazole-based peptidomimetics.
Scheme 47: Tetrazole-based peptidomimetics via an Ugi reaction and a subsequent sigmatropic rearrangement.
Scheme 48: Resin-bound Ugi-approach towards tetrazole-based peptidomimetics.
Scheme 49: Ugi/cyclization approach towards γ/δ/ε-lactam tetrazoles.
Scheme 50: Ugi-3CR to pipecolic acid-based peptidomimetics.
Scheme 51: Staudinger–Aza-Wittig/Ugi-approach towards pipecolic acid peptidomimetics.
Figure 1: The three structural isomers of diketopiperazines. The 2,5-DKP isomer is most common.
Scheme 52: UDC-approach to obtain 2,5-DKPs, either using Armstrong’s isocyanide or via ethylglyoxalate.
Scheme 53: a) Ugi reaction in water gave either 2,5-DKP structures or spiro compounds. b) The Ugi reaction in ...
Scheme 54: Solid-phase approach towards diketopiperazines.
Scheme 55: UDAC-approach towards DKPs.
Scheme 56: The intermediate amide is activated as leaving group by acid and microwave assisted organic synthes...
Scheme 57: UDC-procedure towards active oxytocin inhibitors.
Scheme 58: An improved stereoselective MCR-approach towards the oxytocin inhibitor.
Scheme 59: The less common Ugi reaction towards DKPs, involving a Sn2-substitution.
Figure 2: Spatial similarities between a natural β-turn conformation and a DKP based β-turn mimetic [158].
Scheme 60: Ugi-based syntheses of bicyclic DKPs. The amine component is derived from a coupling between (R)-N-...
Scheme 61: Ugi-based synthesis of β-turn and γ-turn mimetics.
Figure 3: Isocyanide substituted 3,4-dihydropyridin-2-ones, dihydropyridines and the Freidinger lactams. Bio-...
Scheme 62: The mechanism of the 4-CR towards 3,4-dihydropyridine-2-ones 212.
Scheme 63: a) Multiple MCR-approach to provide DHP-peptidomimetic in two-steps. b) A one-pot 6-CR providing th...
Scheme 64: The MCR–alkylation–MCR procedure to obtain either tetrapeptoids or depsipeptides.
Scheme 65: U-3CR/cyclization employing semicarbazone as imine component gave triazine based peptidomimetics.
Scheme 66: 4CR towards triazinane-diones.
Scheme 67: The MCR–alkylation–IMCR-sequence described by our group towards triazinane dione-based peptidomimet...
Scheme 68: Ugi-4CR approaches followed by a cyclization to thiomorpholin-ones (a) and pyrrolidines (b).
Scheme 69: UDC-approach for benzodiazepinones.
Scheme 70: Ugi/Mitsunobu sequence to BDPs.
Scheme 71: A UDAC-approach to BDPs with convertible isocyanides. The corresponding amide is cleaved by microwa...
Scheme 72: microwave assisted post condensation Ugi reaction.
Scheme 73: Benzodiazepinones synthesized via the post-condensation Ugi/ Staudinger–Aza-Wittig cyclization.
Scheme 74: Two Ugi/cyclization approaches utilizing chiral carboxylic acids. Reaction (a) provided the product...
Scheme 75: The mechanism of the Gewald-3CR includes three base-catalysed steps involving first a Knoevnagel–Co...
Scheme 76: Two structural 1,4-thienodiazepine-2,5-dione isomers by U-4CR/cyclization.
Scheme 77: Tetrazole-based diazepinones by UDC-procedure.
Scheme 78: Tetrazole-based BDPs via a sequential Ugi/hydrolysis/coupling.
Scheme 79: MCR synthesis of three different tricyclic BPDs.
Scheme 80: Two similar approaches both involving an Ugi reaction and a Mitsunobu cyclization.
Scheme 81: Mitsunobu–Ugi-approach towards dihydro-1,4-benzoxazepines.
Scheme 82: Ugi reaction towards hetero-aryl fused 5-oxo-1,4-oxazepines.
Scheme 83: a) Ugi/RCM-approach towards nine-membered peptidomimetics b) Sequential peptide-coupling, deprotect...
Scheme 84: Ugi-based synthesis towards cyclic RGD-pentapeptides.
Scheme 85: Ugi/MCR-approach towards 12–15 membered macrocycles.
Scheme 86: Stereoselective Ugi/RCM approach towards 16-membered macrocycles.
Scheme 87: Passerini/RCM-sequence to 22-membered macrocycles.
Scheme 88: UDAC-approach towards 12–18-membered depsipeptides.
Figure 4: Enopeptin A with its more active derivative ADEP-4.
Scheme 89: a) The Joullié–Ugi-approach towards ADEP-4 derivatives b) Ugi-approach for the α,α-dimethylated der...
Scheme 90: Ugi–Click-strategy for 15-membered macrocyclic glyco-peptidomimetics.
Scheme 91: Ugi/Click combinations provided macrocycles containing both a triazole and an oxazole moiety.
Scheme 92: a) A solution-phase procedure towards macrocycles. b) Alternative solid-phase synthesis as was repo...
Scheme 93: Ugi/cyclization towards cyclophane based macrocycles.
Scheme 94: PADAM-strategy towards eurystatin A.
Scheme 95: PADAM-approach for cyclotheanamide.
Scheme 96: A triple MCR-approach affording RGD-pentapeptoids.
Scheme 97: Ugi-MiBs-approach towards peptoid macrocycles.
Scheme 98: Passerini-based MiB approaches towards macrocycles 345 and 346.
Scheme 99: Macrocyclic peptide formation by the use of amphoteric aziridine-based aldehydes.
Beilstein J. Org. Chem. 2014, 10, 481–513, doi:10.3762/bjoc.10.46
Graphical Abstract
Scheme 1: General reaction mechanism for Ag(I)-catalyzed A3-coupling reactions.
Scheme 2: A3-coupling reaction catalyzed by polystyrene-supported NHC–silver halides.
Figure 1: Various NHC–Ag(I) complexes used as catalysts for A3-coupling.
Scheme 3: Proposed reaction mechanism for NHC–AgCl catalyzed A3-coupling reactions.
Scheme 4: Liu’s synthesis of pyrrole-2-carboxaldehydes 4.
Scheme 5: Proposed reaction mechanism for Liu’s synthesis of pyrrole-2-carboxaldehydes 4.
Scheme 6: Gold-catalyzed synthesis of propargylamines 1.
Scheme 7: A3-coupling catalyzed by phosphinamidic Au(III) metallacycle 6.
Scheme 8: Gold-catalyzed KA2-coupling.
Scheme 9: A3-coupling applied to aldehyde-containing oligosaccharides 8.
Scheme 10: A3-MCR for the preparation of propargylamine-substituted indoles 9.
Scheme 11: A3-coupling interceded synthesis of furans 12.
Scheme 12: A3/KA2-coupling mediated synthesis of functionalized dihydropyrazoles 13 and polycyclic dihydropyra...
Scheme 13: Au(I)-catalyzed entry to cyclic carbamimidates 17 via an A3-coupling-type approach.
Scheme 14: Proposed reaction mechanism for the Au(I)-catalyzed synthesis of cyclic carbamimidates 17.
Figure 2: Chiral trans-1-diphenylphosphino-2-aminocyclohexane–Au(I) complex 20.
Scheme 15: A3-coupling-type synthesis of oxazoles 21 catalyzed by Au(III)–salen complex.
Scheme 16: Proposed reaction mechanism for the synthesis of oxazoles 21.
Scheme 17: Synthesis of propargyl ethyl ethers 24 by an A3-coupling-type reaction.
Scheme 18: General mechanism of Ag(I)-catalyzed MCRs of 2-alkynylbenzaldehydes, amines and nucleophiles.
Scheme 19: General synthetic pathway to 1,3-disubstituted-1,2-dihydroisoquinolines.
Scheme 20: Synthesis of 1,3-disubstituted-1,2-dihydroisoquinolines 29.
Scheme 21: Synthesis of 1,3-disubstituted-1,2-dihydroisoquinolines 35 and 36.
Scheme 22: Rh(II)/Ag(I) co-catalyzed synthesis of 1,3-disubstituted-1,2-dihydroisoquinolines 40.
Scheme 23: General synthetic pathway to 2-amino-1,2-dihydroquinolines.
Scheme 24: Synthesis of 2-amino-1,2-dihydroquinolines 47.
Scheme 25: Synthesis of tricyclic H-pyrazolo[5,1-a]isoquinoline 48.
Scheme 26: Synthesis of tricyclic H-pyrazolo[5,1-a]isoquinolines 48.
Scheme 27: Cu(II)/Ag(I) catalyzed synthesis of H-pyrazolo[5,1-a]isoquinolines 48.
Scheme 28: Synthesis of 2-aminopyrazolo[5,1-a]isoquinolines 53.
Scheme 29: Synthesis of 1-(isoquinolin-1-yl)guanidines 55.
Scheme 30: Ag(I)/Cu(I) catalyzed synthesis of 2-amino-H-pyrazolo[5,1-a]isoquinolines 58.
Scheme 31: Ag(I)/Ni(II) co-catalyzed synthesis of 3,4-dihydro-1H-pyridazino[6,1-a]isoquinoline-1,1-dicarboxyla...
Scheme 32: Ag(I) promoted activation of the α-carbon atom of the isocyanide group.
Scheme 33: Synthesis of dihydroimidazoles 65.
Scheme 34: Synthesis of oxazoles 68.
Scheme 35: Stereoselective synthesis of chiral butenolides 71.
Scheme 36: Proposed reaction mechanism for the synthesis of butenolides 71.
Scheme 37: Stereoselective three-component approach to pirrolidines 77 by means of a chiral auxiliary.
Scheme 38: Stereoselective three-component approach to pyrrolidines 81 and 82 by means of a chiral catalyst.
Scheme 39: Synthesis of substituted five-membered carbocyles 86.
Scheme 40: Synthesis of regioisomeric arylnaphthalene lactones.
Scheme 41: Enantioselective synthesis of spiroacetals 96 by Fañanás and Rodríguez [105].
Scheme 42: Enantioselective synthesis of spiroacetals 101 by Gong [106].
Scheme 43: Synthesis of polyfunctionalized fused bicyclic ketals 103 and bridged tricyclic ketals 104.
Scheme 44: Proposed reaction mechanism for the synthesis of ketals 103 and 104.
Scheme 45: Synthesis of β-alkoxyketones 108.
Scheme 46: Synthesis of N-methyl-1,4-dihydropyridines 112.
Scheme 47: Synthesis of tetrahydrocarbazoles 115–117.
Scheme 48: Plausible reaction mechanism for the synthesis of tetrahydrocarbazoles 115–117.
Scheme 49: Carboamination, carboalkoxylation and carbolactonization of terminal alkenes.
Scheme 50: Oxyarylation of alkenes with arylboronic acids and Selectfluor as reoxidant.
Scheme 51: Proposed reaction mechanism for oxyarylation of alkenes.
Scheme 52: Oxyarylation of alkenes with arylsilanes and Selectfluor as reoxidant.
Scheme 53: Oxyarylation of alkenes with arylsilanes and IBA as reoxidant.
Beilstein J. Org. Chem. 2013, 9, 2265–2319, doi:10.3762/bjoc.9.265
Graphical Abstract
Scheme 1: Scaled industrial processes for the synthesis of simple pyridines.
Scheme 2: Synthesis of nicotinic acid from 2-methyl-5-ethylpyridine (1.11).
Scheme 3: Synthesis of 3-picoline and nicotinic acid.
Scheme 4: Synthesis of 3-picoline from 2-methylglutarodinitrile 1.19.
Scheme 5: Picoline-based synthesis of clarinex (no yields reported).
Scheme 6: Mode of action of proton-pump inhibitors and structures of the API’s.
Scheme 7: Hantzsch-like route towards the pyridine rings in common proton pump inhibitors.
Figure 1: Structures of rosiglitazone (1.40) and pioglitazone (1.41).
Scheme 8: Synthesis of rosiglitazone.
Scheme 9: Syntheses of 2-pyridones.
Scheme 10: Synthesis and mechanism of 2-pyrone from malic acid.
Scheme 11: Polymer-assisted synthesis of rosiglitazone.
Scheme 12: Synthesis of pioglitazone.
Scheme 13: Meerwein arylation reaction towards pioglitazone.
Scheme 14: Route towards pioglitazone utilising tyrosine.
Scheme 15: Route towards pioglitazone via Darzens ester formation.
Scheme 16: Syntheses of the thiazolidinedione moiety.
Scheme 17: Synthesis of etoricoxib utilising Negishi and Stille cross-coupling reactions.
Scheme 18: Synthesis of etoricoxib via vinamidinium condensation.
Figure 2: Structures of nalidixic acid, levofloxacin and moxifloxacin.
Scheme 19: Synthesis of moxifloxacin.
Scheme 20: Synthesis of (S,S)-2,8-diazabicyclo[4.3.0]nonane 1.105.
Scheme 21: Synthesis of levofloxacin.
Scheme 22: Alternative approach to the levofloxacin core 1.125.
Figure 3: Structures of nifedipine, amlodipine and clevidipine.
Scheme 23: Mg3N2-mediated synthesis of nifedipine.
Scheme 24: Synthesis of rac-amlodipine as besylate salt.
Scheme 25: Aza Diels–Alder approach towards amlodipine.
Scheme 26: Routes towards clevidipine.
Figure 4: Examples of piperidine containing drugs.
Figure 5: Discovery of tiagabine based on early leads.
Scheme 27: Synthetic sequences to tiagabine.
Figure 6: Structures of solifenacin (2.57) and muscarine (2.58).
Scheme 28: Enantioselective synthesis of solifenacin.
Figure 7: Structures of DPP-4 inhibitors of the gliptin-type.
Scheme 29: Formation of inactive diketopiperazines from cis-rotameric precursors.
Figure 8: Co-crystal structure of carmegliptin bound in the human DPP-4 active site (PDB 3kwf).
Scheme 30: Improved route to carmegliptin.
Figure 9: Structures of lamivudine and zidovudine.
Scheme 31: Typical routes accessing uracil, thymine and cytosine.
Scheme 32: Coupling between pyrimidones and riboses via the Vorbrüggen nucleosidation.
Scheme 33: Synthesis of lamivudine.
Scheme 34: Synthesis of raltegravir.
Scheme 35: Mechanistic studies on the formation of 3.22.
Figure 10: Structures of selected pyrimidine containing drugs.
Scheme 36: General preparation of pyrimidines and dihydropyrimidones.
Scheme 37: Synthesis of imatinib.
Scheme 38: Flow synthesis of imatinib.
Scheme 39: Syntheses of erlotinib.
Scheme 40: Synthesis of erlotinib proceeding via Dimroth rearrangement.
Scheme 41: Synthesis of lapatinib.
Scheme 42: Synthesis of rosuvastatin.
Scheme 43: Alternative preparation of the key aldehyde towards rosuvastatin.
Figure 11: Structure comparison between nicotinic acetylcholine receptor agonists.
Scheme 44: Syntheses of varenicline and its key building block 4.5.
Scheme 45: Synthetic access to eszopiclone and brimonidine via quinoxaline intermediates.
Figure 12: Bortezomib bound in an active site of the yeast 20S proteasome ([114], pdb 2F16).
Scheme 46: Asymmetric synthesis of bortezomib.
Figure 13: Structures of some prominent piperazine containing drugs.
Figure 14: Structural comparison between the core of aplaviroc (4.35) and a type-1 β-turn (4.36).
Scheme 47: Examplary synthesis of an aplaviroc analogue via the Ugi-MCR.
Scheme 48: Syntheses of azelastine (5.1).
Figure 15: Structures of captopril, enalapril and cilazapril.
Scheme 49: Synthesis of cilazapril.
Figure 16: Structures of lamotrigine, ceftriaxone and azapropazone.
Scheme 50: Synthesis of lamotrigine.
Scheme 51: Alternative synthesis of lamotrigine (no yields reported).
Figure 17: Structural comparison between imiquimod and the related adenosine nucleoside.
Scheme 52: Conventional synthesis of imiquimod (no yields reported).
Scheme 53: Synthesis of imiquimod.
Scheme 54: Synthesis of imiquimod via tetrazole formation (not all yields reported).
Figure 18: Structures of various anti HIV-medications.
Scheme 55: Synthesis of abacavir.
Figure 19: Structures of diazepam compared to modern replacements.
Scheme 56: Synthesis of ocinaplon.
Scheme 57: Access to zaleplon and indiplon.
Scheme 58: Different routes towards the required N-methylpyrazole 6.65 of sildenafil.
Scheme 59: Polymer-supported reagents in the synthesis of key aminopyrazole 6.72.
Scheme 60: Early synthetic route to sildenafil.
Scheme 61: Convergent preparations of sildenafil.
Figure 20: Comparison of the structures of sildenafil, tadalafil and vardenafil.
Scheme 62: Short route to imidazotriazinones.
Scheme 63: Alternative route towards vardenafils core imidazotriazinone (6.95).
Scheme 64: Bayer’s approach to the vardenafil core.
Scheme 65: Large scale synthesis of vardenafil.
Scheme 66: Mode of action of temozolomide (6.105) as methylating agent.
Scheme 67: Different routes to temozolomide.
Scheme 68: Safer route towards temozolomide.
Figure 21: Some unreported heterocyclic scaffolds in top market drugs.
Beilstein J. Org. Chem. 2013, 9, 1853–1857, doi:10.3762/bjoc.9.216
Beilstein J. Org. Chem. 2013, 9, 1677–1695, doi:10.3762/bjoc.9.192
Graphical Abstract
Figure 1: The catalyzed enantioselective desymmetrization.
Figure 2: Cinchona alkaloid-derived catalysts OC-1 to OC-11.
Scheme 1: The enantioselective desymmetrization of meso-aziridines in the presence of selected Cinchona alkal...
Figure 3: Cinchona alkaloid-derived catalysts OC-12 to OC-19.
Scheme 2: The enantioselective ring-opening of aziridines in the presence of OC-16.
Scheme 3: OC-16 catalyzed enantioselective ring-opening of aziridines.
Figure 4: The chiral phosphoric acids catalysts OC-20 and OC-21.
Scheme 4: OC-20 and OC-21 catalyzed enantioselective desymmetrization of meso-aziridines.
Figure 5: The proposed mechanism for chiral phosphorous acid-induced enantioselctive desymmetrization of meso...
Scheme 5: OC-21 catalyzed enantioselective desymmetrization of meso-aziridines by Me3SiSPh.
Scheme 6: OC-21 catalyzed the enantioselective desymmetrization of meso-aziridines by Me3SiSePh/PhSeH.
Figure 6: L-Proline and its derivatives OC-22 to OC-27.
Scheme 7: OC-23 catalyzed enantioselective desymmetrization of meso-aziridines.
Figure 7: Proposed bifunctional mode of action of OC-23.
Figure 8: The chiral thioureas OC-28 to OC-44 for the desymmetrization of meso-aziridines.
Scheme 8: Desymmetrization of meso-aziridines with OC-41.
Figure 9: The chiral guanidines (OC-45 to OC-48).
Scheme 9: OC-46 catalyzed desymmetrization of meso-aziridines by arylthiols.
Scheme 10: Desymmetrization of cis-aziridine-2,3-dicarboxylate.
Figure 10: The proposed activation mode of OC-46.
Scheme 11: The enantioselective desymmetrization of meso-aziridines by amine/CS2 in the presence of OC-46.
Figure 11: The chiral 1,2,3-triazolium chlorides OC-49 to OC-55.
Scheme 12: The enantioselective desymmetrization of meso-aziridines by Me3SiX (X = Cl or Br) in the presence o...
Figure 12: Early organocatalysts for enantioselective desymmetrization of meso-epoxides.
Scheme 13: Attempts of enantioselective desymmetrization of meso-epoxides in the presence of OC-58 or OC-60.
Scheme 14: The enantioselective desymmetrization of a meso-epoxide containing one P atom.
Figure 13: Some chiral phosphoramide and chiral phosphine oxides.
Scheme 15: OC-62 catalyzed enantioselective desymmetrization of meso-epoxides by SiCl4.
Figure 14: The proposed mechanism of the chiral HMPA-catalyzed desymmetrization of meso-epoxides.
Scheme 16: The enantioselective desymmetrization of meso-epoxides in the presence of OC-63.
Figure 15: The Chiral phosphine oxides (OC-70 to OC-77) based on an allene backbone.
Scheme 17: OC-73 catalyzed enantioselective desymmetrization of meso-epoxides by SiCl4.
Figure 16: Chiral pyridine N-oxides used in enantioselective desymmetrization of meso-epoxides.
Scheme 18: Catalyzed enantioselective desymmetrization of meso-epoxides in the presence of OC-80 or OC-82.
Figure 17: Chiral pyridine N-oxides OC-85 to OC-94.
Scheme 19: Enantioselective desymmetrization of cis-stilbene oxide by using OC-85 to OC-92 as catalysts.
Figure 18: A novel family of helical chiral pyridine N-oxides OC-95 to OC-97.
Scheme 20: Desymmetrization of meso-epoxides catalyzed by OC-95 to OC-97.
Scheme 21: OC-98 catalyzed enantioselective desymmetrization of meso-epoxides by SiCl4.
Beilstein J. Org. Chem. 2013, 9, 1455–1462, doi:10.3762/bjoc.9.165
Graphical Abstract
Scheme 1: Isolation of trans-dichlorobis(4-iodoanilino-ĸN)palladium(II) and trans-dichlorobis[1,3-diisopropyl...
Scheme 2: Isolation of trans-dichlorobis[1,3-diisopropyl-2-(aryl)guanidino-ĸN(aryl)]palladium(II) complexes (...
Figure 1: (Top) ORTEP view of the centrosymmetric molecule 4a. (Bottom) Crystal packing detail of 4a viewed a...
Figure 2: (Left) ORTEP representation of 4b. (Right) Crystal packing detail of 4b viewed along the a-axis sho...
Figure 3: (Left) ORTEP representation of 4c. (Right) Crystal-packing detail of 4c viewed along the a-axis sho...
Scheme 3: Guanylation reactions of anilines 1a–c by N,N’-diisopropylcarbodiimide (2) catalyzed by Pd(II) salt....
Figure 4: (Left) ORTEP representation of 5a. (Right) Crystal packing details of 5a viewed along the a-axis sh...
Scheme 4: Possible mechanisms for the C–N coupling catalyzed by PdCl2(NCMe)2 in homogeneous phase.
Beilstein J. Org. Chem. 2012, 8, 1901–1908, doi:10.3762/bjoc.8.220
Graphical Abstract
Figure 1: Structure of meridianins A–G.
Scheme 1: Synthesis of functionalized meridianin with an amino group at position 5.
Scheme 2: Synthesis of a functionalized meridianin with an amino group at position 5.
Scheme 3: Synthesis of substrate for the modified Pictet–Spengler reaction.
Scheme 4: The Pictet–Spengler reaction involving substrate 2a. Reagents and conditions: (i) RCHO, 2% triflic ...
Scheme 5: Synthesis of dihydropyrimido-β-carbolines: (i) R-CHO, 2% triflic acid in DMF, 120 °C, 16 h.
Scheme 6: Synthesis of substrates 18a–c for the modified Pictet–Spengler reaction.
Scheme 7: General strategy for the Pictet–Spengler reaction involving substrates 18. Reagents and conditions:...
Beilstein J. Org. Chem. 2012, 8, 1825–1830, doi:10.3762/bjoc.8.209
Graphical Abstract
Scheme 1: Ring-opening polymerization (ROP) of lactide with TBD or the acyclic guanidine 1 as catalysts [16,18].
Scheme 2: Illustration of a photoswitchable guanidine catalyst for the ROP of lactide and the corresponding t...
Scheme 3: Synthesis of guanidine 2E.
Figure 1: ORTEP image of the single-crystal X-ray structure of guanidine 2E, as well as a rotated close-up of...
Figure 2: UV–vis spectra of guanidine 2 in acetonitrile, c = 3.9·10−5 mol/L. (a) E→Z isomerization with irrad...
Scheme 4: Guanidine 11 as a catalyst in the ROP of rac-lactide (catalyst/initiator/monomer ratio = 10:1:100).
Figure 3: Supposed intermediates resulting from either a cyclohexane-substituted guanidine (a) [18] or an aromati...
Beilstein J. Org. Chem. 2012, 8, 1485–1498, doi:10.3762/bjoc.8.168
Graphical Abstract
Scheme 1: Synthesis of guanidine-thiourea organocatalyst 7.
Scheme 2: Henry reaction of 3-phenylpropionaldehyde (8) with nitromethane (9).
Scheme 3: Michael addition of (12) and (14) to trans-β-nitrostyrene (11).
Figure 1: Optimized geometries of four conformers of catalyst 7. Energies are in kcal·mol−1, B3PW91/6–31G(d) ...
Scheme 4: Energy profile for the first step of the reaction between catalyst 7 and malonate 14. Energies are ...
Figure 2: Complexes (CatN1–CatN5) between catalyst 7 and nitrostyrene 11. Energies are in kcal·mol−1, B3PW91/...
Scheme 5: Two possible routes for ternary complex formation. Energies are in kcal·mol−1, B3PW91/6–31G(d) (fir...
Figure 3: Geometries of transition states for R and S products. Relative energies (with respect to Init10) ar...
Figure 4: Geometries of transition states for R and S products. Relative energies (with respect to Init10) ar...
Figure 5: B3PW91/6–31G(d) (first entry), DFT-PCM (second entry), MP2/6–31G(d)//B3PW91/6–31G(d) (third entry) ...
Figure 6: Geometries of transition states for R and S products with 7-TABD catalyst. Relative energies (to In...
Beilstein J. Org. Chem. 2012, 8, 1406–1442, doi:10.3762/bjoc.8.163
Graphical Abstract
Scheme 1: Reactions for the methyl cation affinity (MCA) of a neutral Lewis base (1a), an anionic Lewis base ...
Figure 1: MCA values of monosubstituted amines of general formula Me2N(CH2)nH (n = 1–7, in kJ/mol).
Scheme 2: Systematic dependence of MCA.
Scheme 3: Trends in amine MCA values.
Figure 2: Eclipsing interactions in the best conformation of N+Me(iPr)3 (16Me) (left), and the corresponding ...
Scheme 4: General expression for the chain-length dependence of MCA values.
Figure 3: MCA values of monosubstituted phosphanes of general formula Me2P(CH2)nH (n = 1–8, in kJ/mol).
Figure 4: MCA values of monosubstituted phosphanes of general formula PMe2(CH(CH2)n+1) (n = 1–8, in kJ/mol).
Figure 5: The MCA values of n-butyldiphenylphosphane (102) and its (αα-/ββ-/γγ-) dimethylated analogues.
Figure 6: MCA values of phosphanes Me2P–NR2 with cyclic and acyclic amine substituents.
Figure 7: MCA values of phosphanes PMe2R connected to α,α- and β,β-position of nitrogen containing cyclic sub...
Scheme 5: Reactions for the benzhydryl cation affinity (BHCA) of a Lewis base (5a) and pyridine (5b).
Figure 8: Comparison of BHCA values (kJ/mol) and nucleophilicity parameters N for sterically unbiased pyridin...
Scheme 6: Reactions for the trityl cation affinity (THCA) of a Lewis base (6a) and pyridine (6b).
Figure 9: Comparison of MCA, BHCA, and TCA values of selected Lewis bases.
Scheme 7: Correlations of BHCA/TCA values with the respective MCA data for sterically unbiased systems (exclu...
Figure 10: Scheme for the angle d(RXRR) measurements.
Scheme 8: Reactions for the Mosher's cation affinity (MOSCA) of a Lewis base.
Scheme 9: Reactions for the acetyl cation affinity (ACA) of a Lewis base (9a) and pyridine (9b).
Figure 11: Structure of the acetylated pyridine 380 (380Ac).
Scheme 10: Reaction for the Michael-acceptor affinity (MAA) of a Lewis base.
Figure 12: Inverted reaction free energies for the addition of N- and P-based Lewis bases to three different M...
Figure 13: Correlation between MCA values and affinity values towards three different Michael acceptors.
Scheme 11: (a) General definition for a methyl cation transfer reaction between Lewis bases LB1 and LB2, and (...
Figure 14: The energetically best conformations of Pn-Bu3 (120_1, top) and (120_2, bottom).
Figure 15: Relative order of the conformations 120_1 to 120_7 depending on the level of theory.
Figure 16: The structure of the energetically best conformations of 120Me.
Beilstein J. Org. Chem. 2012, 8, 1344–1351, doi:10.3762/bjoc.8.154
Graphical Abstract
Scheme 1: Retrosynthetic strategy.
Scheme 2: Macrolactonization reactions of seco acids 5 and 6 (for reagents and yields see Table 1 and Table 2).
Figure 1: Analytical HPLC traces of linear peptides. (a) Compound 9 (retention time = 31.5 min); (b) Compound ...
Scheme 3: Synthesis of the dehydroxy side chain 12.
Scheme 4: Synthesis of LI-F04a (1) and analogues 20–23.
Figure 2: Structures and lowest-energy conformers of 24 (left) and 25 (right) obtained using Macromodel. Hydr...
Beilstein J. Org. Chem. 2012, 8, 266–274, doi:10.3762/bjoc.8.28
Graphical Abstract
Scheme 1: Syntheses of benzo[4,5]thieno[3,2-d]pyrimidine 5,5-dioxides (3a–f).
Scheme 2: Syntheses of 3g, 6, and 7.
Figure 1: (a) HOMO and (b) LUMO for 3a, computed with TD-DFT(B3LYP)/6-31+G(d,p). The pink (blue) lobes indica...
Figure 2: The distribution of the HOMO minus LUMO density for 3a, computed with TD-DFT(B3LYP)/6-31+G(d,p). Th...
Figure 3: Schematic diagram of 3a.
Beilstein J. Org. Chem. 2011, 7, 1622–1635, doi:10.3762/bjoc.7.191
Graphical Abstract
Figure 1: Cyanobacteria proliferate in diverse habitats. A) Bloom-forming freshwater cyanobacteria of the gen...
Figure 2: Schematic representation of enzymatic domains in A) nonribosomal peptide synthetases (NRPS); B) pol...
Figure 3: Structures of NRPS and PKS products in freshwater cyanobacteria.
Figure 4: A) Synthesis of the Adda ((2S,3S,8S,9S)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl-4,6-decadienoic...
Figure 5: Structures of NRPS and PKS products in marine cyanobacteria.
Figure 6: A) Formation of the trichloroleucyl starter unit of barbamide (7) synthesis through the non-heme ir...
Figure 7: Structures of NRPS and PKS products in terrestrial cyanobacteria.
Figure 8: Synthesis of the (2S,4S)-4-methylproline moiety of nostopeptolides A (13).
Figure 9: Structures of cyanobacterial peptides that are synthesized ribosomally and post-translationally mod...
Figure 10: Formation of ester linkages and ω-amide linkage in microviridins 17 by the ATP grasp ligases MvdD a...
Figure 11: Structures of cyanobacterial sunscreen compounds.
Beilstein J. Org. Chem. 2011, 7, 442–495, doi:10.3762/bjoc.7.57
Graphical Abstract
Figure 1: Structures of atorvastatin and other commercial statins.
Figure 2: Structure of compactin.
Scheme 1: Synthesis of pentasubstituted pyrroles.
Scheme 2: [3 + 2] Cycloaddition to prepare 5-isopropylpyrroles.
Scheme 3: Regiospecific [3 + 2] cycloaddition to prepare the pyrrole scaffold.
Scheme 4: Formation of the pyrrole core of atorvastatin via [3 + 2] cycloaddition.
Scheme 5: Formation of pyrrole 33 via the Paal–Knorr reaction.
Scheme 6: Convergent synthesis towards atorvastatin.
Figure 3: Binding pocket of sunitinib in the TRK KIT.
Scheme 7: Synthesis of sunitinib.
Scheme 8: Alternative synthesis of sunitinib.
Scheme 9: Key steps in the syntheses of sumatriptan and zolmitriptan.
Scheme 10: Introduction of the N,N-dimethylaminoethyl side chain.
Scheme 11: Japp–Klingemann reaction in the synthesis of sumatriptan.
Scheme 12: Synthesis of the intermediate sulfonyl chlorides 62 and 63.
Scheme 13: Alternative introduction of the sulfonamide.
Scheme 14: Negishi-type coupling to benzylic sulfonamides.
Scheme 15: Heck reaction used to introduce the sulfonamide side chain of naratriptan.
Scheme 16: Synthesis of the oxazolinone appendage of zolmitriptan.
Scheme 17: Grandberg indole synthesis used in the preparation of rizatriptan.
Scheme 18: Improved synthesis of rizatriptan.
Scheme 19: Larock-type synthesis of rizatriptan.
Scheme 20: Synthesis of eletriptan.
Scheme 21: Heck coupling for the indole system in eletriptan.
Scheme 22: Attempted Fischer indole synthesis of elatriptan.
Scheme 23: Successful Fischer indole synthesis for eletriptan.
Scheme 24: Mechanistic rationale for the Bischler–Möhlau reaction.
Scheme 25: Bischler-type indole synthesis used in the fluvastatin sodium synthesis.
Scheme 26: Palladium-mediated synthesis of ondansetron.
Scheme 27: Fischer indole synthesis of ondansetron.
Scheme 28: Optimised Pictet–Spengler reaction towards tadalafil.
Figure 4: Structures of carvedilol 136 and propranolol 137.
Scheme 29: Synthesis of the carbazole core of carvedilol.
Scheme 30: Alternative syntheses of 4-hydroxy-9H-carbazole.
Scheme 31: Convergent synthesis of etodolac.
Scheme 32: Alternative synthesis of etodolac.
Figure 5: Structures of imidazole-containing drugs.
Scheme 33: Synthesis of functionalised imidazoles towards losartan.
Scheme 34: Direct synthesis of the chlorinated imidazole in losartan.
Scheme 35: Synthesis of trisubstituted imidazoles.
Scheme 36: Preparation of the imidazole ring in olmesartan.
Scheme 37: Synthesis of ondansetron.
Scheme 38: Alternative route to ondansetron and its analogues.
Scheme 39: Proton pump inhibitors and synthesis of esomeprazole.
Scheme 40: Synthesis of benzimidazole core pantoprazole.
Figure 6: Structure of rabeprazole 194.
Scheme 41: Synthesis of candesartan.
Scheme 42: Alternative access to the candesartan key intermediate 216.
Scheme 43: .Medicinal chemistry route to telmisartan.
Scheme 44: Improved synthesis of telmisartan.
Scheme 45: Synthesis of zolpidem.
Scheme 46: Copper-catalysed 3-component coupling towards zolpidem.
Figure 7: Structure of celecoxib.
Scheme 47: Preparation of celecoxib.
Scheme 48: Alternative synthesis of celecoxib.
Scheme 49: Regioselective access to celecoxib.
Scheme 50: Synthesis of pazopanib.
Scheme 51: Syntheses of anastrozole, rizatriptan and letrozole.
Scheme 52: Regioselective synthesis of anastrozole.
Scheme 53: Triazine-mediated triazole formation towards anastrozole.
Scheme 54: Alternative routes to 1,2,4-triazoles.
Scheme 55: Initial synthetic route to sitagliptin.
Figure 8: Binding of sitagliptin within DPP-IV.
Scheme 56: The process route to sitagliptin key intermediate 280.
Scheme 57: Synthesis of maraviroc.
Scheme 58: Synthesis of alprazolam.
Scheme 59: The use of N-nitrosoamidine derivatives in the preparation of fused benzodiazepines.
Figure 9: Structures of itraconazole, ravuconazole and voriconazole.
Scheme 60: Synthesis of itraconazole.
Scheme 61: Synthesis of rufinamide.
Scheme 62: Representative tetrazole formation in valsartan.
Figure 10: Structure of tetrazole containing olmesartan, candesartan and irbesartan.
Scheme 63: Early stage introduction of the tetrazole in losartan.
Scheme 64: Synthesis of cilostazol.
Figure 11: Structure of cefdinir.
Scheme 65: Semi-synthesis of cefdinir.
Scheme 66: Thiazole syntheses towards ritonavir.
Scheme 67: Synthesis towards pramipexole.
Scheme 68: Alternative route to pramipexole.
Scheme 69: Synthesis of famotidine.
Scheme 70: Efficient synthesis of the hyperuricemic febuxostat.
Scheme 71: Synthesis of ziprasidone.
Figure 12: Structure of mometasone.
Scheme 72: Industrial access to 2-furoic acid present in mometasone.
Scheme 73: Synthesis of ranitidine from furfuryl alcohol.
Scheme 74: Synthesis of nitrofurantoin.
Scheme 75: Synthesis of benzofuran.
Scheme 76: Synthesis of amiodarone.
Scheme 77: Synthesis of raloxifene.
Scheme 78: Alternative access to the benzo[b]thiophene core of raloxifene.
Scheme 79: Gewald reaction in the synthesis of olanzapine.
Scheme 80: Alternative synthesis of olanzapine.
Figure 13: Access to simple thiophene-containing drugs.
Scheme 81: Synthesis of clopidogrel.
Scheme 82: Pictet–Spengler reaction in the preparation of tetrahydrothieno[3,2-c]pyridine (422).
Scheme 83: Alternative synthesis of key intermediate 422.
Figure 14: Co-crystal structures of timolol (left) and carazolol (right) in the β-adrenergic receptor.
Scheme 84: Synthesis of timolol.
Scheme 85: Synthesis of tizanidine 440.
Scheme 86: Synthesis of leflunomide.
Scheme 87: Synthesis of sulfamethoxazole.
Scheme 88: Synthesis of risperidone.
Figure 15: Relative abundance of selected transformations.
Figure 16: The abundance of heterocycles within top 200 drugs (5-membered rings).
Beilstein J. Org. Chem. 2010, 6, 1056–1060, doi:10.3762/bjoc.6.120
Graphical Abstract
Scheme 1: Synthesis of 2, reagents and conditions: (i) CH2(CN)2, NH4OAc/AcOH, reflux, ZnCl2 (ii) H+/H2O.
Scheme 2: Synthesis of 2, reagents and conditions: (i) CH2(CN)2, NH4OAc/AcOH, reflux, ZnCl2 (ii) H+/H2O.
Scheme 3: Synthesis of 3, reagents and conditions: (i) NC-CH2-CO2Et, NH4OAc/AcOH, reflux, ZnCl2 (ii) H3O+.
Beilstein J. Org. Chem. 2010, 6, No. 65, doi:10.3762/bjoc.6.65
Graphical Abstract
Scheme 1: Preparation of the first electrophilic trifluoromethylating reagent and its reaction with a thiophe...
Scheme 2: Synthetic routes to S-CF3 and Se-CF3 dibenzochalcogenium salts.
Scheme 3: Synthesis of (trifluoromethyl)dibenzotellurophenium salts.
Scheme 4: Nitration of (trifluoromethyl)dibenzochalcogenium salts.
Scheme 5: Synthesis of a sulphonium salt with a bridged oxygen.
Scheme 6: Reactivity of (trifluoromethyl)dibenzochalcogenium salts.
Scheme 7: Pd(II)-Catalyzed ortho-trifluoromethylation of heterocycle-substituted arenes by Umemoto’s reagents....
Scheme 8: Mild electrophilic trifluoromethylation of β-ketoesters and silyl enol ethers.
Scheme 9: Enantioselective electrophilic trifluoromethylation of β-ketoesters.
Scheme 10: Preparation of water-soluble S-(trifluoromethyl)dibenzothiophenium salts.
Scheme 11: Method for large-scale preparation of S-(trifluoromethyl)dibenzothiophenium salts.
Scheme 12: Triflic acid catalyzed synthesis of 5-(trifluoromethyl)thiophenium salts.
Scheme 13: Trifluoromethylation of β-ketoesters and dicyanoalkylidenes by S-(trifluoromethyl)benzothiophenium ...
Scheme 14: Synthesis of chiral S-(trifluoromethyl)benzothiophenium salt 18 and attempt of enantioselective tri...
Scheme 15: Synthesis of O-(trifluoromethyl)dibenzofuranium salts.
Scheme 16: Photochemical O- and N-trifluoromethylation by 20b.
Scheme 17: Thermal O-trifluoromethylation of phenol by diazonium salt 19a. Effect of the counteranion.
Scheme 18: Thermal O- and N-trifluoromethylations.
Scheme 19: Method of preparation of S-(trifluoromethyl)diphenylsulfonium triflates.
Scheme 20: Reactivity of some S-(trifluoromethyl)diarylsulfonium triflates.
Scheme 21: One-pot synthesis of S-(trifluoromethyl)diarylsulfonium triflates.
Scheme 22: One-pot synthesis of Umemoto’s type reagents.
Scheme 23: Preparation of sulfonium salts by transformation of CF3− into CF3+.
Scheme 24: Selected reactions with the new Yagupolskii reagents.
Scheme 25: Synthesis of heteroaryl-substituted sulfonium salts.
Scheme 26: First neutral S-CF3 reagents.
Scheme 27: Synthesis of Togni reagents. aYield for the two-step procedure.
Scheme 28: Trifluoromethylation of C-nucleophiles with 37.
Scheme 29: Selected examples of trifluoromethylation of S-nucleophiles with 37.
Scheme 30: Selected examples of trifluoromethylation of P-nucleophiles with 35 and 37.
Scheme 31: Trifluoromethylation of 2,4,6-trimethylphenol with 35.
Scheme 32: Examples of O-trifluoromethylation of alcohols with 35 in the presence of 1 equiv of Zn(NTf2)2.
Scheme 33: Formation of trifluoromethyl sulfonates from sulfonic acids and 35.
Scheme 34: Organocatalytic α-trifluoromethylation of aldehydes with 37.
Scheme 35: Synthesis of reagent 42 and mechanism of trifluoromethylation.
Scheme 36: Trifluoromethylation of β-ketoesters and dicyanoalkylidenes with 42.
Beilstein J. Org. Chem. 2010, 6, No. 20, doi:10.3762/bjoc.6.20
Graphical Abstract
Figure 1: Schematic representation of sugar aminoacids (SAAs) and (pseudo)amide oligosaccharide mimetics.
Figure 2: Natural SAAs structures and natural nucleosidic antibiotics.
Scheme 1: Synthetic route to the target amide-linked sialooligomers. (a) Fmoc-Cl, NaHCO3, H2O, dioxane, 0 °C....
Figure 3: The general structure of glycoamino acids and their corresponding oligomers.
Figure 4: Conformational analysis of the β(1→2)-amide-linked glucooligomer 9.
Figure 5: Short oligomeric chains of C-glycosyl D-arabino THF amino acid oligomers.
Figure 6: (A) Stereoview of the minimized structure of compound 16 (produced by a 500 ps simulation) that mos...
Figure 7: Structures of linear oxetane-β- and δ-SAA homo-oligomers 19–20.
Figure 8: 10-Membered ring H-bonds in compound 21 consistent with NMR and modelling investigations.
Figure 9: General structure of carbopeptoid-oligonucleotide conjugates.
Figure 10: Protected derivatives of 2,6-diamino-2,6-dideoxy-β-D-glucopyranosyl carboxylic acid 22 and 23.
Figure 11: Cyclic homo-oligomers containing glucopyranoid-SAAs.
Scheme 2: Strategy for solid-phase synthesis of cyclic trimers and tetramers containing pyranoid δ-SAAs.
Figure 12: Cyclic tetramers of L-rhamno- and D-gulo-configured oxetane-SAAs.
Figure 13: Aminoglycosidic antibiotics of the glycocinnamoylspermidine family.
Scheme 3: Synthesis of (thio)trehazoline, via triflate, from β-hydroxy(thio)urea.
Figure 14: Approaches to access pseudoamide-type oligosaccharide mimics.
Figure 15: Calystegine B2 analogues 38 and 39 with urea-linked disaccharide structure.
Figure 16: Rotameric equilibrium shift of 40 by formation of a bidentate hydrogen bond.
Figure 17: Nucleotide analogues with thiourea and S-methylisothiouronium linkers.
Scheme 4: Retrosynthetic approach to synthesize thiourea-linked glycooligomers.
Figure 18: Rotameric equilibria for β-(1→6)-thiourea-linked glucodimer 41.
Figure 19: Schematic representation of (a) cyclodextrin (CDs) and (b) cyclotrehalan (CTs) family members.
Scheme 5: Synthesis of guanidine-linked pseudodisaccharides via carbodiimide.
Figure 20: β(1→6)-Guanidine-linked pseudodi- and pseudotrisaccharides 47 and 48.
Scheme 6: Synthesis of N-benzylguanidine-linked CT2 50.
Figure 21: Structure of RNG and DNG.
Figure 22: Preparation of Fmoc-guanidinium derivatives.
Figure 23: Structures of the homo-oligomeric RNG derivatives 51–55.
Figure 24: Phosphoramidite building block 56.
Figure 25: Structures of DNGs 57–65.
Figure 26: Structure of the phosphoramidite building block 66.
Beilstein J. Org. Chem. 2009, 5, No. 26, doi:10.3762/bjoc.5.26
Graphical Abstract
Scheme 1: Flavin–guanidinium ion conjugates 1 and 2 and tetraacetyl riboflavin (3).
Scheme 2: Synthesis of flavins 1 and 2. Conditions: (i) DMAP, H2O, Δ, 20 h, 71–78%, (ii) HOBt, EDC, NEt(iPr)2...
Figure 1: X-ray crystal structures of the flavin-Kemp’s acids 6 (left) and 9 (right).
Figure 2: Structure of compound 1 in the solid state.
Figure 3: Calculated lowest energy conformation of 1 in the gas phase (AM1, Spartan program package).
Scheme 3: Oxidative photocleavage of dibenzyl phosphate.
Scheme 4: Photoreduction of 4-nitrophenyl phosphate.
Scheme 5: Photo Diels–Alder-reaction of anthracene with N-methyl-maleinimide.
Beilstein J. Org. Chem. 2008, 4, No. 49, doi:10.3762/bjoc.4.49
Graphical Abstract
Scheme 1: Preparation of iminophosphorane 3.
Scheme 2: Preparation of 2-(dialkylamino)-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-ones 6.
Scheme 3: Preparation of 2-alkylamino-5,6-dimethylthieno[2,3-d]pyrimidin-4(3H)-ones 8.